Brms1tm3(EUCOMM)Wtsi
Targeted Allele Detail
|
Symbol: |
Brms1tm3(EUCOMM)Wtsi |
Name: |
breast cancer metastasis-suppressor 1; targeted mutation 3, Wellcome Trust Sanger Institute |
MGI ID: |
MGI:5050951 |
Gene: |
Brms1 Location: Chr19:5091391-5099940 bp, + strand Genetic Position: Chr19, 4.23 cM
|
IMPC: |
Brms1 gene page |
|
Mutant Cell Lines: |
EPD0566_4_A09, EPD0566_4_A11, EPD0566_4_A12, EPD0566_4_B09, EPD0566_4_B10, EPD0566_4_B11, EPD0566_4_B12, EPD0566_4_C10, EPD0566_4_C12, EPD0566_4_D10, EPD0566_4_D11, EPD0566_4_D12, EPD0566_4_E09, EPD0566_4_E11, EPD0566_4_F10, EPD0566_4_F12, EPD0566_4_G09, EPD0566_4_G12, EPD0566_4_H09 |
Germline Transmission: |
Unknown
|
Parent Cell Line: |
JM8A3.N1 (ES Cell)
|
Strain of Origin: |
C57BL/6N-Atm1Brd
|
Project Collection: |
EUCOMM
|
|
Allele Type: |
|
Targeted (Null/knockout, Reporter) |
Mutations: |
|
Insertion, Intragenic deletion
Vector: L1L2_Bact_P
|
|
|
Mutation details: The insertion of the L1L2_Bact_P cassette created a deletion of size 1619 starting at position 5095900 and ending at position 5097519 of Chromosome 19 (Genome Build GRCm39). This deletion results in the removal of functionally critical exon(s). The cassette is composed of an FRT site followed by lacZ sequence and a loxP site. This first loxP site is followed by a neomycin resistance gene under the control of the human beta-actin promoter, SV40 polyA, a second FRT site and a second loxP site.
(J:155845, J:173534)
|
|
|
|
Original: |
J:155845 Wellcome Trust Sanger Institute, Alleles produced for the EUCOMM and EUCOMMTools projects by the Wellcome Trust Sanger Institute. MGI Direct Data Submission. 2010; |
All: |
2 reference(s) |
|